Takeda Pharmaceutical Company Limited (TAK) Oveporexton (TAK-861) Investor Call On Phase 3 Narcolepsy Type 1 Data Presented At World Sleep 2025 (Transcript)

Core Points - The investor call is focused on discussing the Phase III data and commercial readiness of oveporexton [1] - The presentation is conducted in English with simultaneous Japanese translation available [1] - Forward-looking statements will be made during the call, with a reminder that actual results may differ from those discussed [1] Company Overview - Christopher David O'Reilly serves as the Global Head of Investor Relations & Global Finance at Takeda [1] - Andy Plump, the President of R&D, is set to present further details following the introduction [2]